Email updates

Keep up to date with the latest news and content from Molecular Pain and BioMed Central.

Open Access Highly Accessed Research

Toll like receptor (TLR)-4 as a regulator of peripheral endogenous opioid-mediated analgesia in inflammation

Reine-Solange Sauer1, Dagmar Hackel12, Laura Morschel1, Henrike Sahlbach1, Ying Wang1, Shaaban A Mousa3, Norbert Roewer1, Alexander Brack1 and Heike L Rittner1*

Author Affiliations

1 Department of Anesthesiology, University Hospital of Wuerzburg, Oberdürrbacher Strasse 6, D-97080 Würzburg, Germany

2 Department of Anesthesiology and Operative Intensive Care, Campus Benjamin Franklin, Charité, Universitätsmedizin Berlin, Hindenburgdamm 30, D-12200 Berlin, Germany

3 Department of Anesthesiology and Operative Intensive Care, Charité, Universitätsmedizin Berlin, Augustenburger Platz 1, D-13535 Berlin, Germany

For all author emails, please log on.

Molecular Pain 2014, 10:10  doi:10.1186/1744-8069-10-10

Published: 6 February 2014

Abstract

Background

Leukocytes containing opioid peptides locally control inflammatory pain. In the early phase of complete Freund’s adjuvant (CFA)-induced hind paw inflammation, formyl peptides (derived e.g. from Mycobacterium butyricum) trigger the release of opioid peptides from neutrophils contributing to tonic basal antinociception. In the later phase we hypothesized that toll-like-receptor-(TLR)-4 activation of monocytes/macrophages triggers opioid peptide release and thereby stimulates peripheral opioid-dependent antinociception.

Results

In Wistar rats with CFA hind paw inflammation in the later inflammatory phase (48–96 h) systemic leukocyte depletion by cyclophosphamide (CTX) or locally injected naloxone (NLX) further decreased mechanical and thermal nociceptive thresholds. In vitro β-endorphin (β-END) content increased during human monocyte differentiation as well as in anti-inflammatory CD14+CD16- or non-classical M2 macrophages. Monocytes expressing TLR4 dose-dependently released β-END after stimulation with lipopolysaccharide (LPS) dependent on intracellular calcium. Despite TLR4 expression proinflammatory M1 and anti-inflammatory M2 macrophages only secreted opioid peptides in response to ionomycin, a calcium ionophore. Intraplantar injection of LPS as a TLR4 agonist into the inflamed paw elicited an immediate opioid- and dose-dependent antinociception, which was blocked by TAK-242, a small-molecule inhibitor of TLR4, or by peripheral applied NLX. In the later phase LPS lowered mechanical and thermal nociceptive thresholds. Furthermore, local peripheral TLR4 blockade worsened thermal and mechanical nociceptive pain thresholds in CFA inflammation.

Conclusion

Endogenous opioids from monocytes/macrophages mediate endogenous antinociception in the late phase of inflammation. Peripheral TLR4 stimulation acts as a transient counter-regulatory mechanism for inflammatory pain in vivo, and increases the release of opioid peptides from monocytes in vitro. TLR4 antagonists as new treatments for sepsis and neuropathic pain might unexpectedly transiently enhance pain by impairing peripheral opioid analgesia.

Keywords:
Toll like receptors; Analgesia; Inflammatory pain; Endogenous opioids